High incidence rate of vertebral fractures during chronic prednisone treatment, in spite of bisphosphonate or alfacalcidol use. Extension of the "Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis"-trial.

J.N. Hoes; J.W.G. Jacobs; H.M.J. Hulsmans; R.N.J.T.L. de Nijs; W.F. Lems; G.A. bruyn; P.P. Geusens; J.W.J. Bijlsma

High incidence rate of vertebral fractures during chronic prednisone treatment, in spite of bisphosphonate or alfacalcidol use. Extension of the "Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis"-trial.

Translated title of the contribution: High incidence rate of vertebral fractures during chronic prednisone treatment, in spite of bisphosphonate or alfacalcidol use. Extension of the "Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis"-trial.

J.N. Hoes, J.W.G. Jacobs, H.M.J. Hulsmans, R.N.J.T.L. de Nijs, W.F. Lems, G.A. bruyn, P.P. Geusens, J.W.J. Bijlsma

Research output: Contribution to journal › Article › Academic › peer-review

Translated title of the contribution	High incidence rate of vertebral fractures during chronic prednisone treatment, in spite of bisphosphonate or alfacalcidol use. Extension of the "Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis"-trial.
Original language	Undefined/Unknown
Pages (from-to)	354-359
Number of pages	6
Journal	Clinical and Experimental Rheumatology
Volume	28
Issue number	3
Publication status	Published - 2010

Cite this

Hoes, J. N., Jacobs, J. W. G., Hulsmans, H. M. J., de Nijs, R. N. J. T. L., Lems, W. F., bruyn, G. A., Geusens, P. P., & Bijlsma, J. W. J. (2010). High incidence rate of vertebral fractures during chronic prednisone treatment, in spite of bisphosphonate or alfacalcidol use. Extension of the "Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis"-trial. Clinical and Experimental Rheumatology, 28(3), 354-359.

@article{af33b49b5a8f4c5a904f67146554a2c6,

title = "High incidence rate of vertebral fractures during chronic prednisone treatment, in spite of bisphosphonate or alfacalcidol use. Extension of the {"}Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis{"}-trial.",

author = "J.N. Hoes and J.W.G. Jacobs and H.M.J. Hulsmans and \{de Nijs\}, R.N.J.T.L. and W.F. Lems and G.A. bruyn and P.P. Geusens and J.W.J. Bijlsma",

year = "2010",

language = "Undefined/Unknown",

volume = "28",

pages = "354--359",

journal = "Clinical and Experimental Rheumatology",

issn = "0392-856X",

publisher = "Clinical and Experimental Rheumatology S.A.S.",

number = "3",

}

Hoes, JN, Jacobs, JWG, Hulsmans, HMJ, de Nijs, RNJTL, Lems, WF, bruyn, GA, Geusens, PP & Bijlsma, JWJ 2010, 'High incidence rate of vertebral fractures during chronic prednisone treatment, in spite of bisphosphonate or alfacalcidol use. Extension of the "Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis"-trial.', Clinical and Experimental Rheumatology, vol. 28, no. 3, pp. 354-359.

High incidence rate of vertebral fractures during chronic prednisone treatment, in spite of bisphosphonate or alfacalcidol use. Extension of the "Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis"-trial. / Hoes, J.N.; Jacobs, J.W.G.; Hulsmans, H.M.J. et al.
In: Clinical and Experimental Rheumatology, Vol. 28, No. 3, 2010, p. 354-359.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - High incidence rate of vertebral fractures during chronic prednisone treatment, in spite of bisphosphonate or alfacalcidol use. Extension of the "Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis"-trial.

AU - Hoes, J.N.

AU - Jacobs, J.W.G.

AU - Hulsmans, H.M.J.

AU - de Nijs, R.N.J.T.L.

AU - Lems, W.F.

AU - bruyn, G.A.

AU - Geusens, P.P.

AU - Bijlsma, J.W.J.

PY - 2010

Y1 - 2010

M3 - Article

SN - 0392-856X

VL - 28

SP - 354

EP - 359

JO - Clinical and Experimental Rheumatology

JF - Clinical and Experimental Rheumatology

IS - 3

ER -